statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Leap Therapeutics Announces $40 Million Private Placement Leap Therapeutics Announces $40 Million Private Placement PR Newswire CAMBRIDGE, Mass., April 11, 2024 Net proceeds, along with existing...

Leap Therapeutics Announces $40 Million Private Placement

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass., March 18...

Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe...

Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE...

Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients Leap Therapeutics Announces...

Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Volume	334,593.00
52-Wk High	$10.20
52-Wk Low	$1.24

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.59	--	--	N/A
Q4'23	-$0.54	-$0.46	15.44%	BEAT
Q3'23	-$0.58	-$0.51	11.76%	BEAT
Q2'23	-$0.90	-$0.91	-1.56%	MISSED
Q1'23	-$0.86	-$3.20	-272.09%	MISSED

LPTX Leap Therapeutics Inc

About

Feed

News

Earnings

Fundamentals